Special Issue "Clinical Treatment of End-Stage Renal Diseases: Hemodialysis, Peritoneal Dialysis, and Kidney Transplantation"

A special issue of Clinics and Practice (ISSN 2039-7283).

Deadline for manuscript submissions: 30 April 2023 | Viewed by 1258

Special Issue Editors

Special Issue Information

Dear Colleagues,

More than a million deaths per year are caused by kidney disease, and the mortality rate associated with kidney disease is still increasing. Additionally, the rapid increase in the number of patients with end-stage kidney disease (ESKD) requiring dialysis treatment or kidney transplantation is a global problem imposing a high burden on the world health economy. It is, therefore, crucial that ESKD is identified, monitored, and treated and that preventative and therapeutic measures addressing ESKD are systematically implemented worldwide. Nowadays, some kidney-related problems have been thoroughly studied and investigated. However, much is still unknown and/or unclear regarding kidney disease, in terms of pathogenesis, outcomes, and novel treatment strategies.

In this Special Issue, we are honored to invite all researchers and clinicians interested in kidney diseases, dialysis treatment, and kidney transplantation, with regard to these above aspects, to submit contributions that aim to advance knowledge in these essential fields. Original investigations, review articles, and short communications are especially welcome.

Potential topics include, but are not limited to, the following:

  • Aging of the peritoneal dialysis membrane;
  • Pathophysiology and classification of kidney disease;
  • Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients;
  • Association between fear of falling and a history of falls in patients with end-stage renal disease on hemodialysis;
  • Epithelial–mesenchymal transition correlated with renal function;
  • The reversibility of renal fibrosis;
  • Chronic kidney disease and clinical outcomes;
  • Current recommendations regarding the evaluation of cognitive function in organ transplant candidates;
  • Consensus definitions of clinical trial outcomes for kidney failure;
  • Determinants of outcomes of acute kidney injury: clinical predictors;
  • The effect of guided meditation on quality of life in patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis;
  • Current treatment approaches for amyloidosis-associated kidney disease;
  • Treatment of steroid-sensitive nephrotic syndrome: new guidelines.

Best regards,

Dr. Wisit Cheungpasitporn
Dr. Wisit Kaewput
Dr. Charat Thongprayoon
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Clinics and Practice is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • end-stage kidney disease
  • kidney disease
  • dialysis
  • hemodialysis
  • peritoneal dialysis
  • kidney transplantation
  • renal transplantation
  • transplantation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Effects of Mediterranean Diet, DASH Diet, and Plant-Based Diet on Outcomes among End Stage Kidney Disease Patients: A Systematic Review and Meta-Analysis
Clin. Pract. 2023, 13(1), 41-51; https://doi.org/10.3390/clinpract13010004 - 28 Dec 2022
Viewed by 1034
Background: The Mediterranean, Dietary Approach to Stop Hypertension (DASH), and plant-based diets may provide cardiovascular benefit to the general population. However, data on their effect on end stage kidney disease (ESKD) patients are limited. This systematic review aims to assess the impact of [...] Read more.
Background: The Mediterranean, Dietary Approach to Stop Hypertension (DASH), and plant-based diets may provide cardiovascular benefit to the general population. However, data on their effect on end stage kidney disease (ESKD) patients are limited. This systematic review aims to assess the impact of Mediterranean, DASH, and plant-based diets on outcomes among ESKD patients. Methods: A literature review was conducted in EMBASE, MEDLINE, and Cochrane databases from inception through September 2022 to identify studies that assess the clinical outcomes of Mediterranean, DASH, or plant-based diets on ESKD patients on hemodialysis (HD) or peritoneal dialysis (PD). Effect estimates from the individual studies were derived utilizing the random-effect, generic inverse variance approach of DerSimonian and Laird. Results: Seven studies with 9400 ESKD patients (8395 HD and 1005 PD) met the eligibility criteria and were included in the data analysis. Pooled odds ratios (ORs) of mortality for ESKD patients who adhered to the Mediterranean versus plant-based diet were 0.49 (95% CI: 0.07–3.54; two studies, I2 = 67%) and 0.87 (95% CI: 0.75–1.01; two studies, I2 = 0%), respectively. Data on mortality for ESKD patients on a DASH diet were limited to one study with an OR of 1.00 (95% CI: 0.89–1.12). The pooled OR of cardiovascular mortality among ESKD patients who adhered to a plant-based diet was 0.86 (95% CI: 0.68–1.08; two studies, I2 = 0%), compared to those who did not. Data on cardiovascular mortality among those with Mediterranean and DASH diet were limited to one study with ORs of 1.14 (95% CI: 0.90–1.43) and 1.19 (95% CI: 0.99–1.43), respectively. Mediterranean diet adherence was found to be associated with reduced risk of left ventricular hypertrophy (LVH) with an OR of 0.82 (95% CI: 0.68–0.99) in a study including 127 ESKD patients. The risk of hyperkalemia was not significant among those with a plant-based diet with an OR of 1.00 (95% CI: 0.94–1.07) in a study including 150 ESKD patients. Conclusions: While our systematic review demonstrated no significant associations of Mediterranean, DASH, and plant-based diets with reduced all-cause mortality or cardiovascular mortality, there was also no evidence that suggested harmful effects of these diets to ESKD patients. Full article
Show Figures

Figure 1

Back to TopTop